GILD peer analysis
Gilead (GILD) against its competitors: price, today's move, 1-year return and market value side by side.
GILD and its peers
| Company | Price | Today | 1-year return | Market cap |
|---|---|---|---|---|
| ABBV AbbVie | $294.89 | 1.41% | 29.22% | $513.86B |
| AZN AstraZeneca | $186.65 | 7.02% | 13.34% | $270.48B |
| GSK GSK | $49.24 | -0.55% | 4.90% | $97.53B |
| JNJ Johnson & Johnson | $272.61 | -0.22% | 44.20% | $662.49B |
| LLY Eli Lilly | $1,412.98 | -0.32% | 67.32% | $1.22T |
| MRK Merck | $149.00 | -0.35% | 72.69% | $361.02B |
| NVS Novartis | $160.79 | -0.19% | 31.14% | $304.26B |
| PFE Pfizer | $30.45 | -0.23% | 25.36% | $170.71B |
| SNY Sanofi | $44.70 | 0.81% | -12.25% | $103.35B |
| GILD Gilead | $170.68 | 3.06% | 44.11% | $205.35B |
- GILD's peers: ABBV (AbbVie), AZN (AstraZeneca), GSK (GSK), JNJ (Johnson & Johnson), LLY (Eli Lilly), MRK (Merck), NVS (Novartis), PFE (Pfizer).
Updated 2026-11-02 17:55 UTC